GlassScriptPhysician profile
Abbey Aaroe
NPI 1922685189
$6,007.00
in general payments reported to CMS, 2019-2025
18 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $578 · 2022: $646 · 2023: $562 · 2024: $3,843 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,960 · Food and Beverage: $1,690 · Travel and Lodging: $1,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,960.00 |
| Food and Beverage | $1,690.37 |
| Travel and Lodging | $1,132.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $3,925.71 | 2021-2024 | Iovera, Zilretta |
| Collegium Pharmaceutical, INC. | $1,024.63 | 2022-2025 | Xtampza, Belbuca, Nucynta |
| Scilex Pharmaceuticals INC. | $218.01 | 2022-2025 | Ztlido |
| Grt US Holding, INC. | $195.00 | 2022 | |
| Abbvie INC. | $129.71 | 2022-2025 | Ubrelvy |
| Pfizer INC. | $105.71 | 2023-2025 | |
| Amgen INC. | $71.79 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $61.22 | 2023-2025 | Austedo Xr, Austedo Xr |
| Vertex Pharmaceuticals Incorporated | $60.36 | 2024-2025 | |
| Novo Nordisk INC | $32.45 | 2024 | Wegovy |
| Ibsa Pharma INC. | $31.48 | 2023-2024 | Tirosint, Licart, Tirosint |
| Uswm, LLC | $30.19 | 2021-2022 | |
| Saluda Medical Americas, INC. | $29.76 | 2025 | Evoke |
| Medtronic, INC. | $22.82 | 2023 | Intellis Adaptivestim |
| Merz North America, INC. | $20.62 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $18.42 | 2022 | |
| Indivior INC. | $15.93 | 2022 | |
| Biodelivery Sciences International, INC. | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbey Aaroe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.